| Reference |
|---|
Choi W, Lee J, Lee J, Lee S, Kim S. Hepatocyte Growth Factor Regulates Macrophage Transition to the M2 Phenotype and Promotes Murine Skeletal Muscle Regeneration. Front Physiol. 2019;10:914 pubmed publisher |
Giménez Xavier P, Pros E, Bonastre E, Moran S, Aza A, Grana O, et al. Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells. Mol Cancer Ther. 2017;16:1366-1376 pubmed publisher |
Rycaj K, Cho E, Liu X, Chao H, Liu B, Li Q, et al. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells. Oncotarget. 2016;7:14220-40 pubmed publisher |
Valente S, Ciavarella C, Pasanisi E, Ricci F, Stella A, Pasquinelli G. Hepatocyte Growth Factor Effects on Mesenchymal Stem Cells Derived from Human Arteries: A Novel Strategy to Accelerate Vascular Ulcer Wound Healing. Stem Cells Int. 2016;2016:3232859 pubmed publisher |
Jiang W, Ye L, Ruge F, Owen S, Martin T, Sun P, et al. YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells. J Transl Med. 2015;13:280 pubmed publisher |
Ito Y, Correll K, Zemans R, Leslie C, Murphy R, Mason R. Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF-α/EGFR signaling. Am J Physiol Lung Cell Mol Physiol. 2015;308:L1178-88 pubmed publisher |
D Alessandro L, Samaga R, Maiwald T, Rho S, Bonefas S, Raue A, et al. Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling. PLoS Comput Biol. 2015;11:e1004192 pubmed publisher |
Saito S, Morishima K, Ui T, Hoshino H, Matsubara D, Ishikawa S, et al. The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma. BMC Cancer. 2015;15:82 pubmed publisher |
Holland W, Chinn D, Lara P, Gandara D, Mack P. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015;141:615-26 pubmed publisher |
Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, et al. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Br J Cancer. 2014;110:2479-88 pubmed publisher |
Yen B, Yen M, Hsu P, Liu K, Wang C, Bai C, et al. Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3. Stem Cell Reports. 2013;1:139-51 pubmed publisher |
Wu Y, Liu C, Huang M, Lai H, Lee P, Hu R, et al. C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. Cancer Res. 2013;73:5580-90 pubmed publisher |
Breindel J, Haskins J, Cowell E, Zhao M, Nguyen D, Stern D. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res. 2013;73:5053-65 pubmed publisher |
Grugan K, Vega M, Wong G, Diehl J, Bass A, Wong K, et al. A common p53 mutation (R175H) activates c-Met receptor tyrosine kinase to enhance tumor cell invasion. Cancer Biol Ther. 2013;14:853-9 pubmed publisher |
Katayama R, Aoyama A, Yamori T, Qi J, Oh hara T, Song Y, et al. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res. 2013;73:3087-96 pubmed publisher |
Accornero P, Miretti S, Bersani F, Quaglino E, Martignani E, Baratta M. Met receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cells. PLoS ONE. 2012;7:e44982 pubmed publisher |
Muller F, Colla S, Aquilanti E, Manzo V, Genovese G, Lee J, et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012;488:337-42 pubmed publisher |
Goodnough J, Ramos E, Nemeth E, Ganz T. Inhibition of hepcidin transcription by growth factors. Hepatology. 2012;56:291-9 pubmed publisher |
Jiao Y, Ou W, Meng F, Zhou H, Wang A. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer. 2011;10:125 pubmed publisher |
Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer. 2011;105:807-13 pubmed publisher |
Yang X, Turke A, Qi J, Song Y, Rexer B, Miller T, et al. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res. 2011;71:5965-75 pubmed publisher |
Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K. Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br J Cancer. 2011;105:407-12 pubmed publisher |
De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011;103:645-61 pubmed publisher |
Qi J, MCTIGUE M, Rogers A, Lifshits E, Christensen J, Jänne P, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011;71:1081-91 pubmed publisher |
Ou W, Hubert C, Corson J, Bueno R, Flynn D, Sugarbaker D, et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia. 2011;13:12-22 pubmed |
Kongkham P, Onvani S, Smith C, Rutka J. Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma. Transl Oncol. 2010;3:336-43 pubmed |
Qin S, Taglienti M, Nauli S, Contrino L, Takakura A, Zhou J, et al. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest. 2010;120:3617-28 pubmed publisher |
Hoot K, Oka M, Han G, Bottinger E, Zhang Q, Wang X. HGF upregulation contributes to angiogenesis in mice with keratinocyte-specific Smad2 deletion. J Clin Invest. 2010;120:3606-16 pubmed publisher |
Cepero V, Sierra J, Corso S, Ghiso E, Casorzo L, Perera T, et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 2010;70:7580-90 pubmed publisher |
Costa B, Dettori D, Lorenzato A, Bardella C, Coltella N, Martino C, et al. Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB J. 2010;24:2680-8 pubmed publisher |
Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R, et al. A gene-alteration profile of human lung cancer cell lines. Hum Mutat. 2009;30:1199-206 pubmed publisher |
Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009;30:1097-105 pubmed publisher |
Holliday D, Brouilette K, Markert A, Gordon L, Jones J. Novel multicellular organotypic models of normal and malignant breast: tools for dissecting the role of the microenvironment in breast cancer progression. Breast Cancer Res. 2009;11:R3 pubmed publisher |
Sierra J, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med. 2008;205:1673-85 pubmed publisher |
